JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm’s European Analyst Focus List while removing Roche (RHHBY).
Wednesday, January 2, 2019
Significant synergies seen in Omega, MedEquities Realty Trust deal
Highlights include: Anticipated annual FFO, AFFO and FAD accretion of approximately 5c per Omega share. Operator diversification will increase with 9 new operators. Property type diversification will increase non-skilled nursing assets modestly by $296M, including $75M invested in a hospital facility leased to a subsidiary of Baylor, Scott & White Health. Significant synergies expected. Omega will acquire the fee simple interest in 34 facilities operated by 11 operators in 7 states. Omega will acquire approximately $34M in mortgage loans.
Spectrum announces full enrollment of Poziotinib EGFR cohort in ZENITH20 trial
Spectrum Pharmaceuticals announced full enrollment of cohort 1 for previously treated Non-Small Cell Lung Cancer, or NSCLC, patients with EGFR exon 20 insertion mutations with sites across the U.S., Europe, and Canada. The EGFR previously treated cohort is part of the ZENITH20 trial – an open-label, multi-center, global Phase 2 trial evaluating NSCLC patients with EGFR or HER2 exon 20 insertion mutations. Results from this cohort are expected by the second half of 2019.
Cardiovascular Systems gets approval for Diamondback 360 Coronary OAS in Japan
Cardiovascular Systems announced that Japan’s Ministry of Health, Labor and Welfare has approved the Diamondback 360 Coronary Orbital Atherectomy System with Classic Crown and ViperWire Advance Coronary Guidewire FlexTip. Classic Crown is a coronary atherectomy device in the U.S. Classic Crown utilizes a 1.25mm eccentrically mounted diamond-coated crown and a patented combination of centrifugal force and differential sanding to safely modify arterial calcium. This device now features GlideAssist, which allows for tracking, easier removal and smoother repositioning of the device – particularly in challenging anatomies. FlexTip is a unique new atherectomy guidewire with a nitinol core and shapeable stainless-steel tip for increased flexibility and kink-resistance, improved navigation, and reduced guidewire bias in complex coronary vessels. Classic Crown can also be used with ViperWire Advance Coronary Guidewire FlexTip.
Synthorx initiated at H.C. Wainwright
Synthorx initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Debjit Chattopadhyay started Synthorx with a Buy rating and $30 price target. The company’s Expanded Genetic Alphabet technology gives it the ability to manipulate the innate biological interaction of cytokines and adapt them to applications either in oncology or autoimmune diseases, “expanding the versatility and scope of the platform,” says the analyst.
Moderna initiated at Needham
Moderna initiated with a Buy at Needham. Needham analyst Alan Carr kept his Buy rating and a price target of $28 on Moderna, citing his positive view of the company “leveraging an mRNA drug/ drug delivery platform to generate an extensive pipeline across oncology, infectious diseases, cardiology, and rare diseases.” With the company having “generated preclinical and clinical proof of concept of technology”, the analyst expects its first mRNA drug to hit the market around 2024. While mRNA space has other players, Carr sees Moderna having a “particularly strong position for long-term success” thanks to its “extensive resources and know-how.”
Sunesis opens 100 mg cohort of vecabrutinib trial
Sunesis announced that the company has opened the 100 mg cohort in the Phase 1b/2 trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia and other B-cell malignancies. Preliminary safety, pharmacokinetic, and pharmacodynamic data from the now completed 50 mg cohort of the study were recently presented at the American Society of Hematology.
Subscribe to:
Posts (Atom)